12:00 AM
 | 
Feb 18, 2013
 |  BC Week In Review  |  Clinical News  |  Preclinical Results

MiReven, Silence Therapeutics preclinical data

In vitro, miR-7-5p significantly inhibited the migration and invasion of metastatic melanoma cells. The product is a miRNA targeting insulin...

Read the full 90 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >